GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (NAS:ROIV) » Definitions » PE Ratio

ROIV (Roivant Sciences) PE Ratio : 2.25 (As of Nov. 28, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Roivant Sciences PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-11-28), Roivant Sciences's share price is $12.69. Roivant Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $5.65. Therefore, Roivant Sciences's PE Ratio for today is 2.25.

During the past 4 years, Roivant Sciences's highest PE Ratio was 2.32. The lowest was 1.89. And the median was 2.11.

Roivant Sciences's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $5.65.

As of today (2024-11-28), Roivant Sciences's share price is $12.69. Roivant Sciences's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.80. Therefore, Roivant Sciences's PE Ratio without NRI ratio for today is At Loss.

Roivant Sciences's EPS without NRI for the three months ended in Sep. 2024 was $-0.30. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.80.

During the past 3 years, the average EPS without NRI Growth Rate was -15.60% per year.

During the past 4 years, Roivant Sciences's highest 3-Year average EPS without NRI Growth Rate was -15.60% per year. The lowest was -15.60% per year. And the median was -15.60% per year.

Roivant Sciences's EPS (Basic) for the three months ended in Sep. 2024 was $-0.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $6.00.

Back to Basics: PE Ratio


Roivant Sciences PE Ratio Historical Data

The historical data trend for Roivant Sciences's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences PE Ratio Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24
PE Ratio
N/A At Loss At Loss 2.02

Roivant Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss 2.16 2.02 1.90 2.04

Competitive Comparison of Roivant Sciences's PE Ratio

For the Biotechnology subindustry, Roivant Sciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roivant Sciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's PE Ratio falls into.



Roivant Sciences PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Roivant Sciences's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=12.69/5.650
=2.25

Roivant Sciences's Share Price of today is $12.69.
Roivant Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.65.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Roivant Sciences  (NAS:ROIV) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Roivant Sciences PE Ratio Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Roivant Sciences Business Description

Traded in Other Exchanges
Address
50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Executives
Eric Venker officer: President & COO C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Daniel Allen Gold director 6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119
Qvt Financial Lp 10 percent owner, other: Director by Deputization 888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106
Keith S Manchester director C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Rakhi Kumar officer: Chief Accounting Officer C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043
Matthew Gline director, officer: CEO C/O UROVANT SCIENCES, INC., 5151 CALIFORNIA AVENUE, SUITE 250, IRVINE CA 92617
Svf Investments (uk) Ltd 10 percent owner 69 GROSVENOR STREET, LONDON X0 W1K3JP
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Performance Llc 10 percent owner 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Sumitomo Chemical Co., Ltd. 10 percent owner 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Softbank Vision Fund L.p. 10 percent owner AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Richard Pulik officer: CFO SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB
Vivek Ramaswamy director C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902